Joost C.M. Meijers

21.6k total citations · 2 hit papers
354 papers, 16.0k citations indexed

About

Joost C.M. Meijers is a scholar working on Hematology, Genetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Joost C.M. Meijers has authored 354 papers receiving a total of 16.0k indexed citations (citations by other indexed papers that have themselves been cited), including 191 papers in Hematology, 88 papers in Genetics and 61 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Joost C.M. Meijers's work include Blood Coagulation and Thrombosis Mechanisms (164 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (75 papers) and Venous Thromboembolism Diagnosis and Management (57 papers). Joost C.M. Meijers is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (164 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (75 papers) and Venous Thromboembolism Diagnosis and Management (57 papers). Joost C.M. Meijers collaborates with scholars based in Netherlands, United States and United Kingdom. Joost C.M. Meijers's co-authors include Bonno N. Bouma, Marcel Levi, Frits R. Rosendaal, Philip G. de Groot, Ton Lisman, Tom van der Poll, Pieter W. Kamphuisen, Harry R. Büller, Elise S. Eerenberg and Laurent O. Mosnier and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Joost C.M. Meijers

349 papers receiving 15.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

2011 997 citations Elise S. Eerenberg, Pieter W. Kamphuisen et al. Circulation profile →
High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis

2000 518 citations Joost C.M. Meijers, Bonno N. Bouma et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joost C.M. Meijers Netherlands	67	5.9k	3.3k	2.9k	2.6k	2.3k	354	16.0k
Pieter H. Reitsma Netherlands	60	9.0k 1.5×	3.0k 0.9×	4.5k 1.6×	2.3k 0.9×	1.5k 0.6×	248	16.5k
Philip G. de Groot Netherlands	76	12.6k 2.1×	2.7k 0.8×	2.0k 0.7×	1.8k 0.7×	1.5k 0.6×	372	25.3k
Giuseppe Leone Italy	63	6.6k 1.1×	1.3k 0.4×	1.7k 0.6×	3.8k 1.5×	1.5k 0.6×	604	16.2k
Steffen Maßberg Germany	73	4.6k 0.8×	8.0k 2.4×	2.2k 0.8×	975 0.4×	2.5k 1.1×	447	21.6k
Andrew S. Weyrich United States	70	4.8k 0.8×	2.3k 0.7×	1.1k 0.4×	662 0.3×	1.6k 0.7×	169	15.2k
Maureane Hoffman United States	57	5.9k 1.0×	1.5k 0.4×	1.3k 0.4×	1.2k 0.5×	1.1k 0.5×	203	11.6k
Amiram Eldor Israel	51	4.0k 0.7×	2.8k 0.9×	3.1k 1.1×	1.4k 0.5×	545 0.2×	226	11.1k
Charles T. Esmon United States	97	18.3k 3.1×	4.3k 1.3×	5.0k 1.7×	4.7k 1.8×	4.3k 1.9×	321	31.9k
Victor J. Marder United States	51	3.8k 0.6×	2.0k 0.6×	2.3k 0.8×	563 0.2×	1.2k 0.5×	225	10.2k
Pier Luigi Meroni Italy	81	7.6k 1.3×	1.5k 0.5×	691 0.2×	1.0k 0.4×	2.3k 1.0×	621	28.6k

Countries citing papers authored by Joost C.M. Meijers

Since Specialization

Citations

This map shows the geographic impact of Joost C.M. Meijers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joost C.M. Meijers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joost C.M. Meijers more than expected).

Fields of papers citing papers by Joost C.M. Meijers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joost C.M. Meijers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joost C.M. Meijers. The network helps show where Joost C.M. Meijers may publish in the future.

Co-authorship network of co-authors of Joost C.M. Meijers

This figure shows the co-authorship network connecting the top 25 collaborators of Joost C.M. Meijers. A scholar is included among the top collaborators of Joost C.M. Meijers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joost C.M. Meijers. Joost C.M. Meijers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maas, M.A.W., Joost C.M. Meijers, Rienk Nieuwland, et al.. (2023). Anti-high-mobility group box-1 treatment strategies improve trauma-induced coagulopathy in a mouse model of trauma and shock. British Journal of Anaesthesia. 130(6). 687–697. 7 indexed citations

Rein, Nienke van, Tim J. Schuijt, Stella Thomassen, et al.. (2021). Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa. Journal of Thrombosis and Haemostasis. 20(2). 328–338. 5 indexed citations

Chayouâ, Walid, Phillip L.R. Nicolson, Joost C.M. Meijers, et al.. (2021). Antiprothrombin antibodies induce platelet activation: A possible explanation for anti‐FXa therapy failure in patients with antiphospholipid syndrome?. Journal of Thrombosis and Haemostasis. 19(7). 1776–1782. 18 indexed citations

Bakhtiari, Kamran & Joost C.M. Meijers. (2019). In vitro evaluation of factor IX as novel treatment for factor XI deficiency. Blood. 134(6). 573–575. 5 indexed citations

Maat, Steven de, Reiner K. Mailer, Martin Hessing, et al.. (2019). Design and characterization of α1-antitrypsin variants for treatment of contact system–driven thromboinflammation. Blood. 134(19). 1658–1669. 20 indexed citations

Wan, Hoyee, Jinglu Ai, Heyu Ni, et al.. (2018). Role of von Willebrand factor and ADAMTS‐13 in early brain injury after experimental subarachnoid hemorrhage. Journal of Thrombosis and Haemostasis. 16(7). 1413–1422. 16 indexed citations

Hutten, Barbara A., et al.. (2016). PO-28 - Protein C levels are associated with mortality in patients with advanced cancer. Thrombosis Research. 140. S186–S187. 3 indexed citations

Hugenholtz, Greg C.G., Jelle Adelmeijer, Ilona T. A. Pereboom, et al.. (2015). Development of a Hypercoagulable Status in Patients Undergoing Off-Pump Lung Transplantation despite Prolonged Conventional Coagulation Tests. American Journal of Respiratory and Critical Care Medicine. 191(2). 230–233. 10 indexed citations

Goeijenbier, Marco, Koert J. Stittelaar, Kamran Bakhtiari, et al.. (2014). Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets. BMC Microbiology. 14(1). 134–134. 23 indexed citations

10.

Majoor, Christof J., Marianne A. van de Pol, Pieter W. Kamphuisen, et al.. (2014). Evaluation of coagulation activation after Rhinovirus infection in patients with asthma and healthy control subjects: an observational study. Respiratory Research. 15(1). 14–14. 18 indexed citations

11.

Kager, Liesbeth M., W. Joost Wiersinga, Joris J. T. H. Roelofs, et al.. (2013). Endogenous α2-Antiplasmin Is Protective during Severe Gram-Negative Sepsis (Melioidosis). American Journal of Respiratory and Critical Care Medicine. 188(8). 967–975. 28 indexed citations

12.

Lisman, Ton, Kamran Bakhtiari, Jelle Adelmeijer, et al.. (2012). Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. Journal of Thrombosis and Haemostasis. 10(7). 1312–1319. 92 indexed citations

13.

Ağar, Çetin, Philip G. de Groot, Matthias Mörgelin, et al.. (2011). β2-Glycoprotein I: a novel component of innate immunity. Blood. 117(25). 6939–6947. 87 indexed citations

14.

Eerenberg, Elise S., Pieter W. Kamphuisen, Meertien K. Sijpkens, et al.. (2011). Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate. Circulation. 124(14). 1573–1579. 997 indexed citations breakdown →

15.

Lisman, Ton, et al.. (2010). The hemostatic status of pediatric recipients of adult liver grafts suggests that plasma levels of hemostatic proteins are not regulated by the liver. Blood. 117(6). 2070–2072. 14 indexed citations

16.

Nieuwdorp, Max, Marijn C. Meuwese, Hans L. Mooij, et al.. (2008). Tumor necrosis factor-α inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis. 202(1). 296–303. 140 indexed citations

17.

Roelofs, Joris J. T. H., Gwendoline J.D. Teske, Peter I. Bonta, et al.. (2008). Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis. Kidney International. 75(1). 52–59. 30 indexed citations

18.

Hofstra, Jorrit–Jan, et al.. (2007). Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. Critical Care. 11(5). R102–R102. 17 indexed citations

19.

Bornebroek, Marjolijn, Peter A. von dem Borne, Joost Haan, et al.. (1998). Binding of amyloid β precursor protein to coagulation factor XIa in vivo may favour haemorrhagic stroke. Journal of Neurology. 245(2). 111–115. 5 indexed citations

20.

Minnema, Monique C., Philip W. Friederich, Marcel Levi, et al.. (1998). Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.. Journal of Clinical Investigation. 101(1). 10–14. 159 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact